Search Within

Raajit Kumar Rampal

Formats
  1. Meeting Abstract (182)
  2. Journal Article (122)
  3. Review (19)
  4. Research Letter (10)
  5. Book Section (2)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Adult Leukemia (338)
  2. Center for Hematologic Malignancies (338)
  3. Department of Medicine (338)
  4. Hematologic Malignancies, Division of (338)
  5. GSK Faculty (135)
  6. Executive Committee, Center for Hematologic Malignancies (131)

More Groups

People
  1. Ross Levine (87)
  2. Omar Abdel-Wahab (64)
  3. Martin Tallman (41)
  4. Eli Diamond (34)
  5. Ahmet Dogan (30)
  6. Minal Patel (29)

More People

Years
  1. 2025 (10)
  2. 2024 (27)
  3. 2023 (42)
  4. 2022 (36)
  5. 2021 (36)
  6. 2020 (26)

More Years

Publications
  1. Blood (139)
  2. Journal of Clinical Oncology (17)
  3. Blood Advances (15)
  4. Clinical Lymphoma, Myeloma and Leukemia (15)
  5. Haematologica (13)
  6. British Journal of Haematology (10)

More Publications

Publishers
  1. American Society of Hematology (155)
  2. Elsevier Inc. (24)
  3. Nature Publishing Group (21)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (13)
  6. American Association for Cancer Research (12)

More Publishers

Results (338)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Therapeutic efficacy of combined JAK1/2, pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms
    Journal Article

    Rampal, R. K.; Pinzon-Ortiz, M.; Hanasoge Somasundara, A. V.; Durham, B.; Koche, R.; Spitzer, B.; Mowla, S.; Krishnan, A.; Li, B.; An, W.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • LKB1/STK11 is a tumor suppressor in the progression of myeloproliferative neoplasms
    Journal Article

    Marinaccio, C.; Suraneni, P.; Celik, H.; Volk, A.; Wen, Q. J.; Ling, T.; Bulic, M.; Lasho, T.; Koche, R. P.; Famulare, C. A.; more...
    Cancer Discovery (2021)

    Fulltext@MSK | Save
  • CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: Update of manifest phase 2 study
    Meeting Abstract

    Mead, A.; Mascarenhas, J.; Talpaz, M.; Patriarca, A.; Devos, T.; Palandri, F.; Passamonti, F.; Rampal, R.; Kremyanskaya, M.; Scandura, J.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • CPI-0610, bromodomain and extraterminal domain protein (BET) inhibitor, as "add-on" to ruxolitinib, in advanced myelofibrosis patients with suboptimal response: Update of MANIFEST phase 2 study
    Meeting Abstract

    Somervaille, T.; Verstovsek, S.; Mascarenhas, J.; Kremyanskaya, M.; Hoffman, R.; Rampal, R.; Gupta, V.; Talpaz, M.; Granacher, N.; Leber, B.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • CPI-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, as monotherapy in advanced myelofibrosis patients refractory/intolerant to JAK inhibitor: Update from phase 2 MANIFEST study
    Meeting Abstract

    Drummond, M.; Talpaz, M.; Rampal, R.; Verstovsek, S.; Kiladjian, J. J.; Vannucchi, A.; Kremyanskaya, M.; Schiller, G.; Patriarca, A.; Van Gorkom, G.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Addition of parsaclisib (INCB050465), a PI3K delta inhibitor, in patients with suboptimal response to ruxolitinib: A phase 2 study in patients with myelofibrosis
    Meeting Abstract

    Yacoub, A.; Wang, E.; Rampal, R.; Borate, U.; Kremyanskaya, M.; Ali, H.; Hobbs, G.; O'Connell, C.; Assad, A.; Erickson-Viitanen, S.; more...
    British Journal of Haematology (2021)

    Fulltext@MSK | Save
  • Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
    Journal Article

    Xiao, W.; Chan, A.; Waarts, M. R.; Mishra, T.; Liu, Y.; Cai, S. F.; Yao, J.; Gao, Q.; Bowman, R. L.; Koche, R. P.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide
    Research Letter

    Chowdhury, O.; O’Sullivan, J.; Barkas, N.; Wang, G.; Buck, G.; Hamblin, A.; Tefferi, A.; Al-Ali, H. K.; Barosi, G.; Devos, T.; more...
    Leukemia (2021)

    Fulltext@MSK | Save
  • Accelerated and blast phase myeloproliferative neoplasms
    Review

    Jain, T.; Rampal, R. K.
    Hematology/Oncology Clinics of North America (2021)

    Fulltext@MSK | Save
  • The new science and concepts that underlie current and future treatments for myeloproliferative neoplasms
    Editorial

    Hoffman, R.; Levine, R.; Mascarenhas, J.; Rampal, R. K.
    Hematology/Oncology Clinics of North America (2021)

    Fulltext@MSK | Save